Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach

Affiliations

Comment

Damien Bresson et al. Rev Diabet Stud. 2005 Winter.

. 2005 Winter;2(4):187-9; discussion 190-1.

doi: 10.1900/RDS.2005.2.187. Epub 2006 Feb 10.

¹ La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology 3, 10355 Science Center Drive, San Diego, California 92121, USA.

No abstract available

Comment on

Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials.
Chatenoud L, Bach JF. Chatenoud L, et al. Rev Diabet Stud. 2005 Fall;2(3):116-20. doi: 10.1900/RDS.2005.2.116. Epub 2005 Nov 10. Rev Diabet Stud. 2005. PMID: 17491686 Free PMC article. No abstract available.

"Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?
Sia C, Weinem M. Sia C, et al. Rev Diabet Stud. 2006 Winter;3(4):156-60. doi: 10.1900/RDS.2006.3.156. Epub 2007 Feb 10. Rev Diabet Stud. 2006. PMID: 17487339 Free PMC article. No abstract available.
Induction of chimerism permits low-dose islet grafts in the liver or pancreas to reverse refractory autoimmune diabetes.
Zhang C, Wang M, Racine JJ, Liu H, Lin CL, Nair I, Lau J, Cao YA, Todorov I, Atkinson M, Zeng D. Zhang C, et al. Diabetes. 2010 Sep;59(9):2228-36. doi: 10.2337/db10-0450. Epub 2010 Jun 8. Diabetes. 2010. PMID: 20530743 Free PMC article.

1. Chatenoud L, Bach JF. Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials. Rev Diabetic Stud. 2005;2(3):116–120. - PMC - PubMed
1. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692–1698. - PubMed
1. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598–2608. - PubMed
1. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1763–1769. - PMC - PubMed
1. Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol. 1989;142(3):737–743. - PubMed